Maplight Therapeutics (NASDAQ:MPLT) Issues Earnings Results

Maplight Therapeutics (NASDAQ:MPLT) released its quarterly earnings data on Thursday. The company reported ($37.18) earnings per share for the quarter, missing the consensus estimate of ($1.86) by ($35.32), Zacks reports.

Maplight Therapeutics Trading Up 0.8%

Shares of NASDAQ:MPLT opened at $18.49 on Friday. Maplight Therapeutics has a 12 month low of $12.24 and a 12 month high of $20.86.

Analysts Set New Price Targets

Several research firms have recently commented on MPLT. Leerink Partnrs upgraded shares of Maplight Therapeutics to a “strong-buy” rating in a research report on Friday, November 21st. Zacks Research raised Maplight Therapeutics to a “hold” rating in a research note on Monday, November 24th. Jefferies Financial Group started coverage on Maplight Therapeutics in a research report on Friday, November 21st. They set a “buy” rating and a $32.00 price objective for the company. Leerink Partners began coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They set an “outperform” rating and a $30.00 price target on the stock. Finally, Morgan Stanley assumed coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They issued an “overweight” rating and a $34.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $31.00.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients.